Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Slides:

Advertisements

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Advertisements

Assessment of Lymph Node Ratio to Replace the pN Categories System of Classification of the TNM System in Esophageal Squamous Cell Carcinoma Yingjie.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Ratio of Metastatic Lymph Nodes to Total Number of Nodes Resected is Prognostic for Survival in Esophageal Carcinoma Clive J. Kelty, MB, ChB, PhD, FRCSEd,

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Prognostic Impact of Margin Distance and Tumor Spread Through Air Spaces in Limited Resection for Primary Lung Cancer Kyohei Masai, MD, Hiroyuki Sakurai,

Adjuvant Cisplatin and Vinorelbine for Completely Resected Non-small Cell Lung Cancer: Subgroup Analysis of the Lung Adjuvant Cisplatin Evaluation Jean-Yves.

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer Daniel Morgensztern, MD, Saiama.

The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao,

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Frank Detterbeck, MD Journal of Thoracic Oncology

Boundary between N1 and N2 Lymph Node Descriptors in the Subcarinal Zone in Lower Lobe Lung Cancer: A Brief Report Mitsuhiro Isaka, MD, Haruhiko Kondo,

Combined Resection of Superior Vena Cava for Lung Carcinoma: Prognostic Significance of Patterns of Superior Vena Cava Invasion Kenji Suzuki, MD, Hisao.

Pretreatment Quality of Life Is an Independent Prognostic Factor for Overall Survival in Patients with Advanced Stage Non-small Cell Lung Cancer Yingwei.

Predictors of Death, Local Recurrence, and Distant Metastasis in Completely Resected Pathological Stage-I Non–Small-Cell Lung Cancer Jung-Jyh Hung, MD,

Prognostic Factors in Patients with Pathologic T1-2N1M0 Disease in Non-small Cell Carcinoma of the Lung Katsunari Matsuoka, MD, Shinichi Sumitomo, MD,

Clinicopathologic Features of Resected Subcentimeter Lung Cancer

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

An Updated Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated.

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Results of T4 Surgical Cases in the Japanese Lung Cancer Registry Study: Should Mediastinal Fat Tissue Invasion Really be Included in the T4 Category?

The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition Sai-Hong.

A Pragmatic Approach to the Diagnosis of Nodal Micrometastases in Early Stage Non- small Cell Lung Cancer Esther Herpel, MD, Thomas Muley, PhD, Thomas.

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small.

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Clinicopathological Characteristics of Screen-Detected Lung Cancers

Survival Differences by Gender for Resected Non-small Cell Lung Cancer: A Retrospective Analysis of 12,509 Cases in a Japanese Lung Cancer Registry Study

Outcomes of Mediastinoscopy and Surgery with or without Neoadjuvant Therapy in Patients with Non-small Cell Lung Cancer Who are N2 Negative on Positron.

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Prognostic Impact of Node Involvement Pattern in Pulmonary pN1 Squamous Cell Carcinoma Patients Masayuki Nakao, MD, Junji Yoshida, MD, PhD, Genichiro.

Assessment of Lymph Node Ratio to Replace the pN Categories System of Classification of the TNM System in Esophageal Squamous Cell Carcinoma Yingjie.

Results of T4 Surgical Cases in the Japanese Lung Cancer Registry Study: Should Mediastinal Fat Tissue Invasion Really be Included in the T4 Category?

Valerie W Rusch, MD, Ennapadam S Venkatraman, PhD

The Feasibility of Adjuvant Carboplatin and Docetaxel in Patients with Curatively Resected Non-small Cell Lung Cancer Thomas E. Stinchcombe, MD, Harry.

Pulmonary Resection in Patients Aged 80 Years or Over with Clinical Stage I Non-small Cell Lung Cancer: Prognostic Factors for Overall Survival and Risk.

Pathologic N1 non-small cell lung cancer: Correlation between pattern of lymphatic spread and prognosis Alessandro Marra, MD, PhD, Ludger Hillejan, MD,

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Multiple Primary Cancers or Multiple Metastases, That Is the Question

Nabil P. Rizk, MD, Venkatraman E. Seshan, PhD, Manjit S

The International Association for the Study of Lung Cancer Lung Cancer Staging Project Hisao Asamura, MD, Kari Chansky, MS, John Crowley, PhD, Peter.

The Prognostic Impact of Cigarette Smoking on Patients with Non-small Cell Lung Cancer Ryo Maeda, MD, Junji Yoshida, MD, PhD, Genichiro Ishii, MD, PhD,

Number of Metastatic Lymph Nodes in Resected Non–Small Cell Lung Cancer Predicts Patient Survival Jin Gu Lee, MD, Chang Young Lee, MD, In Kyu Park, MD,

The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: Implications for revision of the.

Conditional Survival of Malignant Thymoma Using National Population-Based Surveillance, Epidemiology, and End Results (SEER) Registry (1973–2011) Ellen.

It’s All in the “Swerve of the Curve”

Adjuvant Surgery after Carboplatin and VP16 in Resectable Small Cell Lung Cancer Giulia Veronesi, MD, Paolo Scanagatta, MD, Francesco Leo, MD, Tommaso.

Immune-Modulating Vaccines in Non-small Cell Lung Cancer

Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD, Yasunori Sohara, MD, Ryosuke Tsuchiya, MD,

Pulmonary Resection for Metastases from Colorectal Cancer

Significance of Smoking as a Postoperative Prognostic Factor in Patients with Non- small Cell Lung Cancer Takeshi Hanagiri, MD, PhD, Kenji Sugio, MD,

Lobe-Specific Nodal Dissection for Clinical Stage I and II NSCLC: Japanese Multi- Institutional Retrospective Study Using a Propensity Score Analysis

MTP19-01: T4 N0/N1 nonsmall cell lung cancer can be cured as a first line treatment with an expected five year survival rate as high as 43% provided a.

Validity of International Association for the Study of Lung Cancer Proposals for the Revision of N Descriptors in Lung Cancer Jin Gu Lee, MD, Chang Young.

The Clinical Impact of Solid and Micropapillary Patterns in Resected Lung Adenocarcinoma Naoki Yanagawa, MD, PhD, Satoshi Shiono, MD, PhD, Masami Abiko,

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Completely Resected Non-Small Cell Lung Cancer: Reconsidering Prognostic Value and Significance of N2 Metastases Marc Riquet, MD, PhD, Patrick Bagan,

A Proposal for Combination of Lymph Node Ratio and Anatomic Location of Involved Lymph Nodes for Nodal Classification in Non–Small Cell Lung Cancer Xiao.

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

Razvan Diaconescu, MD, Chantal Lafond, MD, Renaud Whittom, MD

Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey.

Presentation transcript:

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage Classification? Shenhai Wei, MD, PhD, Hisao Asamura, MD, Riken Kawachi, MD, Hiroyuki Sakurai, MD, Shun-ichi Watanabe, MD Journal of Thoracic Oncology Volume 6, Issue 2, Pages 310-318 (February 2011) DOI: 10.1097/JTO.0b013e3181ff9b45 Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Patients included in this study. Journal of Thoracic Oncology 2011 6, 310-318DOI: (10.1097/JTO.0b013e3181ff9b45) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Distribution of the metastatic lymph nodes in pN1 and pN2 stage. Journal of Thoracic Oncology 2011 6, 310-318DOI: (10.1097/JTO.0b013e3181ff9b45) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 The survival curves according to different number of metastatic lymph nodes. Journal of Thoracic Oncology 2011 6, 310-318DOI: (10.1097/JTO.0b013e3181ff9b45) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 Disease-free survival (DFS) and overall survival (OS) according to pN stage classification and nN category. A, DFS curves according to pN stage classification. Five-year DFS rate for pN0, pN1, and pN2 was 83.2%, 37.3%, and 24.5%, respectively. B, OS curves according to pN stage classification. Five-year OS rate for pN0, pN1, and pN2 was 89.2%, 55.4%, and 47.8%, respectively. C, DFS curves according to nN category. Five-year DFS rate for nN0, nN1, nN2, and nN3 was 83.2%, 44.1%, 23.0%, and 6.5%, respectively. D, OS curves according to nN category. Five-year OS rate for nN0, nN1, nN2, and nN3 was 89.2%, 65.1%, 42.1% and 22.4%, respectively. Journal of Thoracic Oncology 2011 6, 310-318DOI: (10.1097/JTO.0b013e3181ff9b45) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 5 Overall survival (OS) curves according to nN category across each pT stage. A, OS curves according to nN category in pT1 patients. Five-year OS rate for nN0, nN1, nN2, and nN3 was 94.1%, 81.5%, 65.5%, and 50.1%, respectively. B, OS curves according to nN category in pT2 patients. Five-year OS rate for nN0, nN1, nN2, and nN3 was 82.6%, 55.0%, 31.9%, and 22.3%, respectively. C, OS curves according to nN category in pT3 patients. Five-year OS rate for nN0, nN1, nN2, and nN3 was 87.04%, 38.5%, 10.4% and 0%, respectively. D, OS curves according to nN category in pT3 patients. Five-year OS rate for nN0, nN1, nN2, and nN3 was 43.0%, 56.6%, 47.8%, and 0%, respectively. Journal of Thoracic Oncology 2011 6, 310-318DOI: (10.1097/JTO.0b013e3181ff9b45) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 6 Disease-free survival (DFS) and overall survival (OS) according to nN subgroup when pN1 and pN2 patients were subdivided into different nN subgroups. A, DFS curves according to nN subgroup in pN1 patients. Five-year DFS rate for nN1, nN2, and nN3 subgroup was 41.6%, 25.0%, and 40%, respectively. B, OS curves according to nN subgroup in pN1 patients. Five-year OS rate for nN1, nN2, and nN3 subgroup was 61.5%, 35.6%, and 53.3%, respectively. C, DFS curves according to nN subgroup in pN2 patients. Five-year DFS rate for nN1, nN2, and nN3 subgroup was 48.0%, 23.0%, and 3.9%, respectively. D, OS curves according to nN subgroup in pN2 patients. Five-year OS rate for nN1, nN2, and nN3 subgroup was 72.0%, 45.6%, and 19.4%, respectively. Journal of Thoracic Oncology 2011 6, 310-318DOI: (10.1097/JTO.0b013e3181ff9b45) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 7 Disease-free survival (DFS) and overall survival (OS) according to pN subgroup when nN1, nN2, and nN3 patients were subdivided into pN1 and pN2 subgroups. A, DFS curves according to pN subgroup in nN1 patients. Five-year DFS rate for pN1 and pN2 subgroup was 41.6% and 48.0%, respectively. B, OS curves according to pN subgroup in nN1 patients. Five-year OS rate for pN1 and pN2 subgroup was 61.5% and 72.0%, respectively. C, DFS curves according to pN subgroup in nN2 patients. Five-year DFS rate for pN1 and pN2 subgroup was 25.5% and 23.0%, respectively. D, OS curves according to pN subgroup in nN2 patients. Five-year OS rate for pN1 and pN2 subgroup was 35.6% and 45.6%, respectively. E, DFS curves according to pN subgroup in nN3 patients. Five-year DFS rate for pN1 and pN2 subgroup was 40.0% and 3.9%, respectively. F, OS curves according to pN subgroup in nN3 patients. Five-year OS rate for pN1 and pN2 subgroup was 53.3% and 19.4%, respectively. Journal of Thoracic Oncology 2011 6, 310-318DOI: (10.1097/JTO.0b013e3181ff9b45) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions